Core Viewpoint - Lutai A (000726.SZ) has sold financial assets to improve liquidity, with the sale of Rongchang Biotech shares impacting net profit by 81.04 million yuan, exceeding 10% of the company's audited net profit for the last fiscal year [1][3]. Financial Performance - In 2024, Lutai A achieved revenue of 6.091 billion yuan, a year-on-year increase of 2.17%, and a net profit of 410 million yuan, up 1.7% [1][6]. - The company completed a total cash dividend distribution of 204 million yuan for 2024, representing approximately 49.84% of the net profit for the year [1][8]. Shareholding and Asset Management - As of December 31, 2024, Lutai A held 3.918 million shares of Rongchang Biotech, accounting for 0.72% of its total equity, with a book value of 118 million yuan [2][3]. - Following the sale, Lutai A retains 612,600 shares of Rongchang Biotech [2][3]. Market Activity - The stock price of Rongchang Biotech fell by 18.36% on June 26, 2024, closing at 60.7 yuan per share, despite a year-to-date increase of 97.85% [4]. - The current market value of Lutai A's remaining shares in Rongchang Biotech is approximately 37.185 million yuan [4]. Business Operations - Lutai A's textile and apparel segment generated revenue of 5.707 billion yuan in 2024, reflecting a 2.74% increase, with fabric and clothing products contributing 4.335 billion yuan and 1.372 billion yuan, respectively [6]. - The production volumes for fabrics and shirts were 205 million meters and 18.2526 million pieces, showing growth of 1.45% and 3.18% year-on-year [6]. Investment and Capital Management - Lutai A raised 1.4 billion yuan through convertible bonds in 2020, with net proceeds of 1.388 billion yuan allocated to strategic projects [7]. - The company has invested 586 million yuan and 358 million yuan in its functional fabric smart eco-park and overseas high-end fabric product line projects, respectively, with both projects having exceeded their investment targets [7]. Share Buyback and Dividends - In 2024, Lutai A repurchased B-shares for a total of 37.867 million yuan, contributing to a total cash distribution (dividends and buybacks) of 242 million yuan, which is 59.03% of the net profit for the year [8].

Core Viewpoint - The domestic innovative drug sector has shifted from a previous upward trend to a phase of volatility, with market participants showing a tendency to buy more as prices drop, indicating a potential long-term investment interest despite short-term fluctuations [1][2]. Group 1: Market Trends - From June 16 to June 25, medical-themed ETFs saw a net inflow of over 6.4 billion yuan, with several leading innovative drug ETFs attracting more than 1.5 billion yuan [1]. - Despite a significant drop of 8.51% in the Hong Kong innovative drug index from June 16 to June 20, funds continued to flow into innovative drug ETFs, with net inflows of 8.89 billion yuan and 7.10 billion yuan for specific ETFs during that period [2]. - The innovative drug sector experienced a brief recovery at the beginning of the week, with continued strong inflows into ETFs, totaling over 6.4 billion yuan since June 16 [2]. Group 2: Company Developments - On June 26, the innovative drug sector faced another decline, influenced by the announcement from Rongchang Biopharmaceuticals regarding a licensing deal with Vor Bio, which raised concerns about the actual value of business development (BD) deals compared to market expectations [3]. - Rongchang Biopharmaceuticals will receive 125 million USD in cash and warrants, with potential milestone payments reaching up to 4.105 billion USD, but the initial payment was perceived as low, leading to market skepticism [3]. - Following the announcement, Rongchang's A-shares fell over 18% and H-shares dropped over 11%, impacting several ETFs heavily invested in the stock [3]. Group 3: Investment Insights - Analysts suggest that the innovative drug sector's high volatility necessitates a longer-term investment perspective, as short-term trading often fails to yield satisfactory returns [5]. - Companies with higher confidence, better competitive positioning, and more complete business logic are viewed as more favorable investment targets in the innovative drug space [5]. - The innovative drug sector's underlying logic for recent growth includes asset revaluation and the influx of multinational corporations (MNCs) into China for business development opportunities [4].

Meeting Overview - The first H-share class shareholders' meeting of Rongchang Biopharmaceuticals was held on June 26, 2025, in Yantai, Shandong Province [1] - A total of 111 ordinary shareholders attended the meeting, with 108 being A-share shareholders and 3 being H-share shareholders [1] Voting Results - The voting results showed that the majority of the proposals were approved, with ordinary shareholders voting 99.9689% in favor of the proposals [1][2] - A-share shareholders voted 99.9848% in favor, while H-share shareholders' voting results were not detailed in the provided data [1][2] Legal Compliance - The meeting was conducted in accordance with the Company Law and the company's articles of association, ensuring that the procedures and voting methods were legally valid [1][7] - The lawyers present confirmed that the meeting's procedures and results were compliant with relevant laws and regulations [7]

Market Overview - The market experienced a strong performance yesterday but faced a quick decline today, with the Hang Seng Index closing down 0.61% [1] - UBS warned that the current short squeeze in the US stock market may be nearing its end, with their tracked short squeeze index rising 43% recently [1] - Apollo Global's chief economist predicts a slowdown in US GDP growth to 1.2% by 2025, with inflation remaining around 3% and unemployment potentially rising to 4.4% or higher [1] Economic Indicators - Concerns were raised by Jerome Powell regarding the reliability of economic data collected by US government agencies, suggesting potential overestimations due to budget cuts [1] - The Hong Kong Monetary Authority bought HKD 94.2 billion (approximately RMB 86.13 billion) to support the currency, indicating liquidity tightening in the market [2] Sector Performance - The securities sector failed to maintain its upward momentum, with leading firms like Guotai Junan International seeing a drop of over 4% [3] - The Hong Kong government announced a new policy to promote digital assets, aiming to position the city as a global innovation hub in this field [3] - Consumer sectors are gaining attention, with the "Hong Kong Happy Shopping Festival" set to offer over HKD 1.9 billion in discounts, attracting significant participation from brands [5] Company Developments - Rongchang Bio announced a deal with VorBio for USD 125 million in cash and warrants, but the market reacted negatively, viewing the price as too low [4] - Li Ning's major shareholder has been increasing their stake, which is expected to support the company's operational stability [8] - Li Ning's revenue from running products is projected to grow by 25% in 2024, with core categories like running, basketball, and training accounting for 64% of retail revenue [9] Stock Movements - Stocks in the aviation sector are expected to rise due to increased ticket bookings for the summer travel season, with domestic bookings up about 5% year-on-year [7] - The military sector saw gains following comments from Trump regarding potential conflicts, with companies like China Shipbuilding Defense and AVIC rising over 6% and 1.68% respectively [6] - The weakening US dollar has led to a rise in commodity stocks, with companies like Minmetals Resources and China Hongqiao seeing increases of over 4% [5]

Group 1 - The Hang Seng Index fell by 0.61% on June 26, with southbound trading totaling HKD 167.21 billion, including HKD 86.25 billion in buying and HKD 80.96 billion in selling, resulting in a net buying amount of HKD 5.29 billion [1] - The southbound trading through the Shenzhen Stock Connect amounted to HKD 52.41 billion, with net buying of HKD 2.04 billion, while the Shanghai Stock Connect saw a total of HKD 114.80 billion with net buying of HKD 3.24 billion [1] - Among the actively traded stocks, Guotai Junan International had the highest trading volume at HKD 31.72 billion, followed by Hong Kong Travel and China Everbright Holdings with HKD 8.89 billion and HKD 5.91 billion respectively [1] Group 2 - Semiconductor Manufacturing International Corporation (SMIC) recorded a net buying amount of HKD 8.96 billion, with a closing price increase of 1.02% [2] - China Construction Bank and Xinda Biopharmaceuticals also saw significant net buying amounts of HKD 5.82 billion and HKD 6.75 billion respectively, while Tencent Holdings experienced the highest net selling of HKD 5.71 billion, despite a slight price increase of 0.10% [2] - A total of 7 stocks, including SMIC and Hong Kong Travel, were active in both the Shenzhen and Shanghai Stock Connects, with SMIC's total trading amount reaching HKD 4.63 billion and a net buying of HKD 8.96 billion [2]

Core Insights - On June 26, several stocks including China Everbright Holdings, Hong Kong Travel, Ocean Park, and Rongchang Biopharmaceutical made their debut on the active trading list of Hong Kong Stock Connect, marking their first appearance in the past month [1][2] - The total trading volume of active stocks on June 26 reached 752.26 billion HKD, accounting for 44.99% of the total trading amount for the day, with a net buying amount of 37.13 billion HKD [1][2] Trading Activity Summary - China Everbright Holdings had a trading volume of 59.07 billion HKD with a net buying of 0.94 billion HKD, closing up by 6.19% [2] - Hong Kong Travel recorded a trading volume of 88.87 billion HKD and a net buying of 5.30 billion HKD, closing up by 85.98% [2] - Ocean Park had a trading volume of 16.72 billion HKD with a net buying of 0.23 billion HKD, closing up by 11.27% [2] - Rongchang Biopharmaceutical saw a trading volume of 12.64 billion HKD with a net buying of 1.13 billion HKD, but closed down by 11.71% [2] Most Active Stocks - The most active stock by trading volume was Guotai Junan International, with a trading amount of 317.23 billion HKD [1][2] - Alibaba and Tencent Holdings were the most frequently listed stocks in the past month, each appearing 22 times on the active trading list [1][2]

Summary of Key Points Core Viewpoint - Rongchang Biologics (688331) experienced a significant decline in stock price, closing at 60.70 yuan, down 18.36% on June 26, with a trading volume of 1.48 billion yuan and a turnover rate of 14.96% [2][3]. Trading Activity - The stock was listed on the daily trading list due to a price drop of 15% [2]. - The top five trading departments accounted for a total transaction of 607 million yuan, with buying transactions amounting to 235 million yuan and selling transactions totaling 372 million yuan, resulting in a net sell of 137 million yuan [2]. - Among the top buying departments, two were institutional special seats, with buying amounts of 629.26 million yuan and 545.06 million yuan respectively, while the Shanghai-Hong Kong Stock Connect was the third largest buyer with 495.44 million yuan [2][3]. - The selling departments included one institutional special seat with a selling amount of 857.04 million yuan, and the Shanghai-Hong Kong Stock Connect was the fourth largest seller with 635.25 million yuan [2][3]. Net Capital Flow - The stock saw a net outflow of 110 million yuan in main capital throughout the day [3].

Core Insights - On June 26, 2025, Guotai Junan International (01788), Hong Kong Travel (00308), and China Everbright Holdings (00165) ranked as the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 24.285 billion, 6.964 billion, and 4.470 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Guotai Junan International (01788), Hong Kong Travel (00308), and Xiaomi Group-W (01810) were the top three companies, with trading amounts of 7.437 billion, 1.923 billion, and 1.730 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Top active companies by trading volume include: - Guotai Junan International (01788): 24.285 billion with a net buy of 26.0143 million - Hong Kong Travel (00308): 6.964 billion with a net buy of 400 million - China Everbright Holdings (00165): 4.470 billion with a net buy of 7.03114 million - Shandong Molong (00568): 4.252 billion with a net buy of 93.5208 million - Xiaomi Group-W (01810): 3.235 billion with a net buy of 78.9768 million [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top active companies by trading volume include: - Guotai Junan International (01788): 7.437 billion with a net buy of 233 million - Hong Kong Travel (00308): 1.923 billion with a net buy of 130 million - Xiaomi Group-W (01810): 1.730 billion with a net buy of 123 million - SMIC (00981): 1.652 billion with a net buy of 532 million - China Everbright Holdings (00165): 1.437 billion with a net buy of 24.1098 million [2]

6月26日港股市场，北水成交净买入52.86亿港元，其中港股通(沪)成交净买入32.41亿港元，港股通(深) 成交净买入20.45亿港元。 中芯国际(00981)获净买入8.96亿港元。消息面上，美拟收紧半导体技术豁免。东方证券指出，台积电、 三星电子和SK海力士等半导体制造商在中国大陆的工厂在其全球供应链中具有重要地位。这些工厂同 时具有中国大陆的市场、政策、资源和人才等成本优势，及母公司的技术和设备优势。若豁免权取消， 其相较本土晶圆厂竞争设备和技术优势将受削弱，利好本土晶圆厂。 | 港股通(沪)活跃成交股 | | --- | | 荣昌生物 | 6.88亿 | 5.75亿 | 12.64亿 | | --- | --- | --- | --- | | HK 09995 | | | +1.13 亿 | | 腾讯控股 | 2.91亿 | 8.62亿 | 11.54亿 | | HK 00700 | | | -5.71亿 | | 信达生物 | 8.95亿 | 2.20亿 | 11.15亿 | | HK 01801 | | | +6.75亿 | 港股通(深)活跃成交股 北水净买入最多的个股是中芯国际(00981)、信 ...

Group 1 - The core point of the article is that Rongchang Biologics has entered into a collaboration with VorBio, granting exclusive global rights (excluding Greater China) for the development, production, and commercialization of its proprietary drug, Tai Tasi Pi, which is a dual-target fusion protein [1][2] - The collaboration involves an upfront payment of $125 million, which includes a $45 million upfront payment and $80 million in warrants, potentially allowing VorBio to issue 320 million shares, representing 23% of its expanded share capital [1] - The total potential transaction value could reach $4.23 billion, including milestone payments of up to $4.105 billion and sales royalties in the high single to double-digit percentage range [1] Group 2 - The partnership is expected to accelerate the overseas market expansion of Tai Tasi Pi, providing innovative treatment options for global patients and enhancing the company's brand value and international influence [2] - Following the announcement, the market reacted negatively, with Rongchang Biologics' stock price dropping significantly, including an 18.36% decline in A-shares, despite a year-to-date increase of over 101% prior to the announcement [2] - Analysts noted that the upfront payment amount was perceived as low and that VorBio's smaller company size contributed to the market's disappointment regarding the collaboration's potential [2] Group 3 - Tai Tasi Pi is the world's first recombinant B lymphocyte stimulator (BLyS)/proliferation-inducing ligand (APRIL) dual-target fusion protein, designed to inhibit abnormal differentiation and maturation of B cells, thereby reducing pathogenic antibody production [1] - The drug has already been approved in China for the treatment of myasthenia gravis (MG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), with MG receiving fast track designation from the FDA and orphan drug status from both the US and EU regulatory agencies [1] - Sales of Tai Tasi Pi are projected to exceed 1.5 million units in 2024 [1]